Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dianne Dehaven

Clinical Nurse Specialist, Psychiatric/Mental Health Walnut Hills, OH Clinical Nurse Specialist

NPI 1629126388 CMS profile 10986064

1501 Madison Rd, Walnut Hills, OH 45206

Open in the dashboard

General payments

$8,217

269 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dianne Dehaven of Walnut Hills, OH is reported in the CMS Open Payments database as having received $8,217 across 269 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $624 26
2024 General $1,143 67
2023 General $1,600 76
2022 General $846 65
2021 General $4,004 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dianne Dehaven
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Dianne Dehaven were reported at $624. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Dianne Dehaven Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $4,004 $153 $44–$540 $132
2022 $846 $207 $60–$748 $149
2023 $1,600 $197 $55–$898 $160
2024 $1,143 $189 $49–$804 $164
2025 $624 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,708 95 payments
  2. Lundbeck LLC $1,099 75 payments
  3. Otsuka America Pharmaceutical, Inc. $997 41 payments
  4. Teva Pharmaceuticals USA, Inc. $305 10 payments
  5. ITI, Inc. $281 13 payments
  6. Janssen Pharmaceuticals, Inc $279 13 payments
  7. Alkermes, Inc. $148 3 payments
  8. Neurocrine Biosciences, Inc. $144 6 payments
  9. Axsome Therapeutics, Inc. $81 4 payments
  10. Indivior Inc. $72 3 payments
  11. Other $103 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,503 262 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,575 3 payments
  3. Education $122 2 payments
  4. Travel and Lodging $17 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $4,542 91 payments
  2. ABILIFY MAINTENA $949 52 payments
  3. REXULTI Psychiatry $805 36 payments
  4. REXULTI Psychiatry $618 42 payments
  5. ABILIFY ASIMTUFII $543 21 payments
  6. INVEGA SUSTENNA $279 13 payments
  7. CAPLYTA $261 12 payments
  8. UZEDY $179 4 payments
  9. VRAYLAR Neuroscience $178 5 payments
  10. INVEGA TRINZA $164 10 payments
  11. Other $1,199 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 70 drugs

Part D claims

6,341

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$2,307,847

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

23.7%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 187 $565,159
Invega Trinza Paliperidone Palmitate Brand 43 $372,737
Austedo Xr Deutetrabenazine Brand 34 $324,720
Ingrezza Valbenazine Tosylate Brand 55 $240,785
Vraylar Cariprazine Hcl Brand 145 $211,422
Rexulti Brexpiprazole Brand 77 $118,124
Abilify Maintena Aripiprazole Brand 43 $115,454
Uzedy Risperidone Brand 22 $67,082
Lurasidone Hcl Generic 74 $33,048
Aripiprazole Generic 223 $32,366

The 10 drugs with the highest cost, of 70 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$7,420

Medicare's payments for the services billed

Medicare patients

65

Average age 47

Services billed

135

29 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 46%
Depression 23%
Atrial fibrillation 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $270
  • Otsuka America Pharmaceutical, Inc. $86
$357 77 —
VRAYLAR
  • AbbVie, Inc. $301
$301 145 —
ABILIFY MAINTENA
  • Lundbeck LLC $129
$129 43 —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $106
$106 — —
PERSERIS
  • Indivior Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record